Multiple sclerosis shortens life expectancy by about 7 years on average. A 60-year population study from Western Norway found a median life expectancy of 74.7 years for people with MS, compared to 81.8 years in the general population. That gap is real, but it also means most people with MS live into their 70s. MS is a serious chronic disease, not typically a rapid killer.
Still, the overall mortality rate for people with MS is nearly three times higher than for the general population. How that risk plays out depends heavily on the type of MS, how far disability progresses, what treatments are used, and how well complications are managed.
How MS Type Affects Survival
The two main courses of MS carry very different life expectancies. People with relapsing-remitting MS (the most common form, where symptoms flare and then improve) had a median life expectancy of 77.8 years in the Norwegian study. Those with primary progressive MS, where disability accumulates steadily from the start without distinct relapses, had a median life expectancy of 71.4 years. That’s roughly a 6-year difference between the two types.
Measured from the time symptoms first appeared, the gap is even more striking. Median survival from onset was 42.8 years for relapsing-remitting MS and 25.5 years for primary progressive MS. The mortality risk in primary progressive MS was about twice as high as in relapsing-remitting MS when compared against the general population. This makes sense: progressive disease leads to more severe disability earlier, and severe disability is where the most dangerous complications arise.
What Actually Causes Death in MS
MS itself rarely kills directly. Instead, the severe disability that develops in advanced stages creates vulnerabilities to infections and respiratory problems that can become fatal. In one large study, respiratory complications accounted for roughly 47% of all MS-related deaths.
The most common contributors to death in people with MS include:
- Aspiration pneumonia: When nerve damage impairs swallowing, food or liquid can enter the lungs. People with MS were more than 7 times as likely to have aspiration pneumonia contribute to their death compared to the general population.
- Respiratory infections: Lung infections contributed to about 22.5% of MS-attributed deaths, nearly double the 12.7% rate in all deaths.
- Urinary tract infections: Bladder dysfunction is common in MS, and UTIs contributed to 8% of MS-related deaths, compared to under 2% in the general population. The risk was especially high for men, with a nearly 15-fold increase.
- Pressure ulcers and sepsis: Immobility leads to skin breakdown, which contributed to about 3% of MS-attributed deaths, often by allowing infections to reach the bloodstream.
The important detail here is that many of these complications are preventable or manageable. Swallowing therapy, bladder management, mobility aids, and regular skin checks can reduce the risk of these causes of death significantly. Researchers have noted that the conditions driving MS mortality are largely tied to severe disability and immobility, meaning that slowing disability progression has a direct effect on survival.
How Disability Level Shapes Risk
Not everyone with MS reaches the level of disability where these fatal complications become likely. The risk of dying is closely tied to how much physical function has been lost. In one five-year study, the mortality rate was 24% among patients with the most severe disability (those who were essentially bedbound or required a wheelchair with limited arm function). For people with mild or moderate disability, mortality during the same period was far lower.
Respiratory failure typically occurs in the terminal stages of MS and is usually accompanied by significant paralysis affecting the limbs or the muscles controlling swallowing and breathing. The underlying cause is nerve damage in the brainstem or spinal cord that disrupts signals to respiratory muscles. This can lead to weakened cough reflexes, abnormal breathing patterns, and eventually the inability to clear the lungs effectively. These problems are rare early in the disease and become more common only as disability advances substantially.
Treatment Has Changed the Picture
Modern disease-modifying therapies have meaningfully improved survival. Norwegian registry data showed that after these treatments became widely available, mortality in people with MS was more than halved. A Canadian study found that exposure to any disease-modifying therapy was associated with a 26% lower risk of death. A separate analysis found that treated patients had a 44% lower risk of death compared to untreated patients.
These treatments work by reducing the frequency of relapses and slowing disability progression, which in turn delays or prevents the advanced complications that drive most MS deaths. Someone diagnosed today and started on effective treatment has a substantially better outlook than the historical averages suggest. The 7-year life expectancy gap comes from data spanning six decades, including eras before effective treatments existed.
Cardiovascular Disease and Other Health Risks
MS doesn’t exist in isolation. Conditions like diabetes, heart disease, chronic lung disease, and depression are all associated with increased mortality risk in people with MS, just as they are in the general population. A large Canadian study found that median survival was 75.9 years in people with MS compared to 83.4 years in matched controls, and comorbidities contributed to that gap in both groups similarly.
Cardiovascular disease deserves particular attention. A 25-year analysis of U.S. death records found that deaths involving both MS and cardiovascular disease increased significantly between 1999 and 2023, with a sharp rise between 2018 and 2021. This may reflect both better MS survival (people living long enough to develop heart disease) and the reduced physical activity that comes with disability. Managing blood pressure, cholesterol, and blood sugar matters just as much for someone with MS as for anyone else.
Mental Health and Suicide Risk
The psychological burden of MS also affects mortality. People with MS have an 83% higher risk of dying by suicide compared to the general population. Living with unpredictable symptoms, progressive disability, fatigue, and cognitive changes takes a toll. Depression is common in MS, both as a reaction to the diagnosis and as a direct result of nerve damage affecting mood-regulating brain circuits. Recognizing and treating depression is a meaningful part of improving both quality of life and survival.
Putting the Numbers in Perspective
MS is not the death sentence it was once considered. Most people diagnosed today will live into their 70s. The disease shortens life expectancy by several years on average, but that average includes people diagnosed decades ago without access to current treatments, people with the most aggressive forms of the disease, and people with significant comorbidities.
The biggest factors determining how MS affects your lifespan are the type of MS you have, how quickly disability progresses, whether you’re on effective treatment, and how well complications like infections and immobility are managed. For someone with relapsing-remitting MS who responds well to treatment and maintains their mobility, the life expectancy gap is likely smaller than the population-wide average of 7 years. For someone with primary progressive MS and advancing disability, the risks are higher and the timeline shorter.